Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
12.36B
Market cap12.36B
Price-Earnings ratio
-30.32
Price-Earnings ratio-30.32
Dividend yield
Dividend yield
Average volume
2.31M
Average volume2.31M
High today
$75.19
High today$75.19
Low today
$73.35
Low today$73.35
Open price
$73.74
Open price$73.74
Volume
1.71M
Volume1.71M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $74.79. The company's market cap stands at 12.36B, with a P/E ratio of -30.32.

On 2026-04-03, Ionis Pharmaceuticals(IONS) stock moved within a range of $73.35 to $75.19. With shares now at $74.79, the stock is trading +2.0% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 1.71M, compared to an average daily volume of 2.31M.

The stock's 52-week range extends from a low of $23.95 to a high of $86.74.

The stock's 52-week range extends from a low of $23.95 to a high of $86.74.

IONS News

TipRanks 3d
Ionis: Olezarsen’s Expanded Global Opportunity and Strengthened Royalty Streams Support Reiterated Buy and $120 Target

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ionis Pharmaceuticals and keeping the price target at $120.00. End of Quarter Sale - 50%...

Simply Wall St 7d
Is It Time To Reassess Ionis Pharmaceuticals After Its Strong One Year Share Price Run?

If you are wondering whether Ionis Pharmaceuticals at around US$74.24 is offering fair value or not, it helps to look past the headline price and focus on what...

Is It Time To Reassess Ionis Pharmaceuticals After Its Strong One Year Share Price Run?

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
23.8%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.